Clinical Study to Evaluate XS411 in Treatment of Early-onset Parkinson's Disease — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Clinical Study to Evaluate XS411 in Treatment of Early-onset Parkinson's Disease — Stella

Home/Parkinson Disease (PD)/

View on ClinicalTrials.gov

Recruiting

Back to Parkinson Disease (PD) trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Huashan Hospital, Fudan University, Shanghai, Shanghai Municipality

Key details

Phase

Early testing / Safety & dosing

Sponsor

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.

Enrollment target

~90 participants

Started

September 2025

Primary completion

March 2028

Age range

18 Years – 70 Years

Last updated December 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.